Pharmaceuticals, Biotechnology and Life Sciences
Swiss-based biopharmaceutical drugmaker Debiopharm presented results for its novel IAP antagonist Debio 1143 from phase two trial, for high-risk Head and Neck cancer patients, which met its primary goal of increasing treatment efficacy compared to CRT and placebo.
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
Debiopharm International, a Swiss-based global biopharmaceutical company, has started testing its antibiotic afabicin (Debio 1450) for the treatment of staphylococcal bone and joint infections in a clinical phase II study.
Swiss-based global biopharmaceutical company Debiopharm Group will break up partnership with Allergan, and will transfer commercialisation licence for Trelstar in the US and Canada.